D B Gissi1, A Tarsitano2, E Leonardi3, A Gabusi4, F Neri5, C Marchetti2, L Montebugnoli4, M P Foschini3, L Morandi3. 1. Department of Biomedical and Neuromotor Sciences, Section of Oral Sciences, University of Bologna, Italy. Electronic address: davide.gissi@unibo.it. 2. Department of Biomedical and Neuromotor Sciences, University of Bologna, Section of Maxillofacial Surgery at Policlinico S. Orsola-Malpighi, Bologna, Italy. 3. Department of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology at Bellaria Hospital, University of Bologna, Italy. 4. Department of Biomedical and Neuromotor Sciences, Section of Oral Sciences, University of Bologna, Italy. 5. Unit of Maxillofacial Surgery, Bellaria Hospital, Bologna, Italy.
Abstract
OBJECTIVES: A novel classification based on molecular methods to assess clonality defines three types of secondary oral squamous cell carcinoma (OSCC): second primary tumour (SPT) independent from the index tumour, local recurrence (LR), clonally related to the primary tumour, and second field tumour (SFT), derived from the same genetically altered mucosal field as the primary tumour. The present study applied mtDNA analysis in a group of patients experiencing a second loco-regional neoplastic manifestation. The purpose was to differentiate secondary tumours into LRs, SPTs and SFTs and evaluate the prognostic impact in terms of survival rate. MATERIAL AND METHODS: The study population comprised 23 patients who experienced a second neoplastic lesion after a surgical resection of primary OSCC. mtDNA D-loop analysis was applied in paired neoplastic lesions and in clinically and histologically normal mucosa. On the basis of mtDNA results, the second OSCC was classified as LR or SPT or SFT. Disease-free survival was defined as the duration between the appearance of the second neoplastic lesion and death of disease, or last follow-up visit. RESULTS: Seven secondary tumours were classified as LR, 12 as SFT, 4 as SPT. An altered mucosal field proved a variable significantly related to a better survival rate (p<0.05); 2/12 (16.6%) SFT events failed as compared to 5/7 LRs (71.4%) and 3/4 SPTs (75%). CONCLUSION: mtDNA analysis may be considered a useful tool to differentiate secondary tumours and might influence the choice of the most appropriate treatment in patients with multiple OSCCs.
OBJECTIVES: A novel classification based on molecular methods to assess clonality defines three types of secondary oral squamous cell carcinoma (OSCC): second primary tumour (SPT) independent from the index tumour, local recurrence (LR), clonally related to the primary tumour, and second field tumour (SFT), derived from the same genetically altered mucosal field as the primary tumour. The present study applied mtDNA analysis in a group of patients experiencing a second loco-regional neoplastic manifestation. The purpose was to differentiate secondary tumours into LRs, SPTs and SFTs and evaluate the prognostic impact in terms of survival rate. MATERIAL AND METHODS: The study population comprised 23 patients who experienced a second neoplastic lesion after a surgical resection of primary OSCC. mtDNA D-loop analysis was applied in paired neoplastic lesions and in clinically and histologically normal mucosa. On the basis of mtDNA results, the second OSCC was classified as LR or SPT or SFT. Disease-free survival was defined as the duration between the appearance of the second neoplastic lesion and death of disease, or last follow-up visit. RESULTS: Seven secondary tumours were classified as LR, 12 as SFT, 4 as SPT. An altered mucosal field proved a variable significantly related to a better survival rate (p<0.05); 2/12 (16.6%) SFT events failed as compared to 5/7 LRs (71.4%) and 3/4 SPTs (75%). CONCLUSION: mtDNA analysis may be considered a useful tool to differentiate secondary tumours and might influence the choice of the most appropriate treatment in patients with multiple OSCCs.
Authors: Davide B Gissi; Luca Morandi; Andrea Gabusi; Achille Tarsitano; Claudio Marchetti; Francesca Cura; Annalisa Palmieri; Lucio Montebugnoli; Sofia Asioli; Maria P Foschini; Luca Scapoli Journal: Int J Mol Sci Date: 2018-06-16 Impact factor: 5.923
Authors: Davide B Gissi; Achille Tarsitano; Andrea Gabusi; Roberto Rossi; Giuseppe Attardo; Jacopo Lenzi; Claudio Marchetti; Lucio Montebugnoli; Maria P Foschini; Luca Morandi Journal: J Clin Med Date: 2019-12-02 Impact factor: 4.241
Authors: Julia Rosemann; Lisa Müller; Jonas Weiße; Matthias Kappler; Alexander W Eckert; Markus Glaß; Danny Misiak; Stefan Hüttelmaier; Wolfgang G Ballhausen; Mechthild Hatzfeld; Monika Haemmerle; Tony Gutschner Journal: Mol Cancer Date: 2021-06-11 Impact factor: 27.401